Share Price and Basic Stock Data
Last Updated: November 20, 2025, 7:33 pm
| PEG Ratio | 2.36 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Jyothy Labs Ltd operates in the personal care industry, with a current market capitalization of ₹11,318 Cr and a share price of ₹308. The company has demonstrated a solid revenue trajectory, with sales increasing from ₹2,196 Cr in FY 2022 to ₹2,486 Cr in FY 2023, and further rising to ₹2,757 Cr in FY 2024. The latest quarterly sales figures reveal a robust growth pattern, recording ₹732 Cr in September 2023 and ₹678 Cr in December 2023. The sales growth reflects a consistent upward trend, with the company achieving a notable increase in quarterly sales from ₹547 Cr in March 2022 to ₹687 Cr in June 2023. This performance is indicative of positive consumer sentiment and effective market strategies. The company’s ability to maintain a steady increase in sales amidst competitive pressures highlights its strong position in the industry.
Profitability and Efficiency Metrics
Jyothy Labs Ltd has showcased impressive profitability metrics, with a reported net profit of ₹370 Cr for FY 2025, up from ₹240 Cr in FY 2023. The operating profit margin (OPM) stood at 17% for FY 2025, reflecting a significant improvement from the 11% reported in FY 2022. The company’s operating profit rose from ₹248 Cr in FY 2022 to ₹500 Cr in FY 2025, illustrating enhanced operational efficiency. The interest coverage ratio (ICR) of 93.62x indicates a strong ability to meet interest obligations, substantially higher than typical industry benchmarks. Additionally, return on equity (ROE) at 19.0% and return on capital employed (ROCE) at 24.6% further affirm the firm’s effective capital utilization. However, the net profit margin declined slightly from 13.39% in FY 2024 to 13.00% in FY 2025, signaling potential pressure on profitability moving forward.
Balance Sheet Strength and Financial Ratios
The balance sheet of Jyothy Labs Ltd reflects significant strength, with total reserves increasing to ₹2,013 Cr in FY 2025, while borrowings remained low at ₹61 Cr. This translates to a debt-to-equity ratio of 0.00, indicating minimal reliance on debt financing, which is advantageous for financial stability. The current ratio stands at 2.76, suggesting robust liquidity and the ability to cover short-term obligations comfortably. Furthermore, the company has maintained a high book value per share of ₹55.81, increasing from ₹49.30 in FY 2024. The price-to-book value ratio of 5.89x suggests that the stock is priced at a premium, which may reflect investor confidence in future growth prospects. However, the enterprise value (EV) of ₹11,925.68 Cr compared to the net operating revenue indicates a higher valuation relative to sales, which could be a consideration for investors weighing potential returns against market expectations.
Shareholding Pattern and Investor Confidence
As of March 2025, the shareholding pattern of Jyothy Labs Ltd indicates a strong promoter holding of 62.88%, which has remained relatively stable over the past few quarters. Foreign institutional investors (FIIs) hold 12.11%, while domestic institutional investors (DIIs) account for 16.08% of the shares. The public ownership stands at 8.91%, reflecting a diverse but concentrated ownership structure. The increase in the number of shareholders from 1,30,772 in December 2022 to 2,17,305 by March 2025 indicates growing investor interest and confidence in the company. This trend is further supported by the decrease in FII holdings from 14.35% in December 2024 to the current 12.11%, which may suggest a recalibration of investment strategies among institutional players. The stability in promoter holdings may contribute to investor confidence, as it signals commitment to the company’s long-term vision.
Outlook, Risks, and Final Insight
Looking ahead, Jyothy Labs Ltd is poised for continued growth, driven by its robust revenue trends and strong profitability metrics. However, potential risks include rising competition in the personal care sector and fluctuations in raw material costs, which could impact margins. The company’s ability to innovate and adapt to changing consumer preferences will be crucial. Additionally, while the low debt levels provide a cushion against financial distress, any significant downturn in sales could strain liquidity. The high valuation metrics may pose a risk if market conditions change or if the company fails to meet growth expectations. In conclusion, Jyothy Labs Ltd presents a compelling investment opportunity, provided it can navigate potential challenges while leveraging its strengths in operational efficiency and market positioning.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Jyothy Labs Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Honasa Consumer Ltd | 9,441 Cr. | 290 | 334/190 | 75.9 | 38.8 | 0.00 % | 7.44 % | 5.51 % | 10.0 |
| Ambica Agarbathies Aroma & Industries Ltd | 44.7 Cr. | 26.0 | 37.0/23.3 | 87.6 | 65.2 | 0.00 % | 7.49 % | 0.45 % | 10.0 |
| Ador Multi Products Ltd | 103 Cr. | 108 | 119/23.4 | 32.5 | 0.00 % | 11.4 % | 3.09 % | 10.0 | |
| Kaya Ltd | 602 Cr. | 399 | 488/204 | 60.9 | 0.00 % | 2.50 % | % | 10.0 | |
| Jyothy Labs Ltd | 11,389 Cr. | 310 | 433/268 | 31.1 | 55.8 | 1.13 % | 24.6 % | 19.0 % | 1.00 |
| Industry Average | 71,486.43 Cr | 1,939.20 | 57.25 | 112.44 | 0.74% | 29.21% | 23.91% | 4.94 |
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 547 | 597 | 659 | 613 | 617 | 687 | 732 | 678 | 660 | 742 | 734 | 704 | 667 |
| Expenses | 489 | 537 | 579 | 528 | 526 | 570 | 597 | 559 | 552 | 608 | 595 | 589 | 555 |
| Operating Profit | 57 | 60 | 80 | 84 | 91 | 117 | 135 | 119 | 108 | 133 | 138 | 116 | 112 |
| OPM % | 10% | 10% | 12% | 14% | 15% | 17% | 18% | 18% | 16% | 18% | 19% | 16% | 17% |
| Other Income | 6 | 13 | 12 | 15 | 6 | 17 | 13 | 11 | 13 | 14 | 13 | 14 | 11 |
| Interest | 3 | 3 | 3 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Depreciation | 15 | 13 | 13 | 12 | 12 | 12 | 12 | 13 | 13 | 13 | 14 | 14 | 15 |
| Profit before tax | 45 | 57 | 76 | 84 | 82 | 121 | 135 | 115 | 107 | 132 | 136 | 114 | 107 |
| Tax % | 17% | 16% | 14% | 20% | 28% | 21% | 23% | 21% | 27% | 23% | 23% | 23% | 29% |
| Net Profit | 37 | 48 | 65 | 67 | 59 | 96 | 104 | 91 | 78 | 102 | 105 | 87 | 76 |
| EPS in Rs | 1.03 | 1.32 | 1.76 | 1.84 | 1.61 | 2.62 | 2.84 | 2.48 | 2.13 | 2.77 | 2.86 | 2.38 | 2.08 |
Last Updated: May 31, 2025, 8:43 am
Below is a detailed analysis of the quarterly data for Jyothy Labs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 667.00 Cr.. The value appears to be declining and may need further review. It has decreased from 704.00 Cr. (Dec 2024) to 667.00 Cr., marking a decrease of 37.00 Cr..
- For Expenses, as of Mar 2025, the value is 555.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 589.00 Cr. (Dec 2024) to 555.00 Cr., marking a decrease of 34.00 Cr..
- For Operating Profit, as of Mar 2025, the value is 112.00 Cr.. The value appears to be declining and may need further review. It has decreased from 116.00 Cr. (Dec 2024) to 112.00 Cr., marking a decrease of 4.00 Cr..
- For OPM %, as of Mar 2025, the value is 17.00%. The value appears strong and on an upward trend. It has increased from 16.00% (Dec 2024) to 17.00%, marking an increase of 1.00%.
- For Other Income, as of Mar 2025, the value is 11.00 Cr.. The value appears to be declining and may need further review. It has decreased from 14.00 Cr. (Dec 2024) to 11.00 Cr., marking a decrease of 3.00 Cr..
- For Interest, as of Mar 2025, the value is 2.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.00 Cr. (Dec 2024) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Mar 2025, the value is 15.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14.00 Cr. (Dec 2024) to 15.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Mar 2025, the value is 107.00 Cr.. The value appears to be declining and may need further review. It has decreased from 114.00 Cr. (Dec 2024) to 107.00 Cr., marking a decrease of 7.00 Cr..
- For Tax %, as of Mar 2025, the value is 29.00%. The value appears to be increasing, which may not be favorable. It has increased from 23.00% (Dec 2024) to 29.00%, marking an increase of 6.00%.
- For Net Profit, as of Mar 2025, the value is 76.00 Cr.. The value appears to be declining and may need further review. It has decreased from 87.00 Cr. (Dec 2024) to 76.00 Cr., marking a decrease of 11.00 Cr..
- For EPS in Rs, as of Mar 2025, the value is 2.08. The value appears to be declining and may need further review. It has decreased from 2.38 (Dec 2024) to 2.08, marking a decrease of 0.30.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: May 15, 2025, 6:11 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,324 | 1,515 | 1,593 | 1,683 | 1,672 | 1,814 | 1,711 | 1,909 | 2,196 | 2,486 | 2,757 | 2,847 |
| Expenses | 1,170 | 1,350 | 1,370 | 1,428 | 1,415 | 1,532 | 1,460 | 1,594 | 1,948 | 2,170 | 2,277 | 2,347 |
| Operating Profit | 154 | 164 | 223 | 255 | 257 | 282 | 251 | 315 | 248 | 316 | 480 | 500 |
| OPM % | 12% | 11% | 14% | 15% | 15% | 16% | 15% | 16% | 11% | 13% | 17% | 18% |
| Other Income | 8 | 6 | 13 | 10 | 62 | 27 | 16 | -5 | 19 | 47 | 54 | 51 |
| Interest | 55 | 14 | 62 | 56 | 48 | 35 | 33 | 19 | 12 | 13 | 5 | 6 |
| Depreciation | 24 | 33 | 31 | 30 | 31 | 31 | 53 | 56 | 58 | 50 | 50 | 56 |
| Profit before tax | 82 | 125 | 143 | 179 | 241 | 243 | 182 | 235 | 197 | 299 | 479 | 489 |
| Tax % | 1% | 3% | 48% | -14% | 26% | 19% | 10% | 19% | 19% | 20% | 23% | 24% |
| Net Profit | 81 | 121 | 74 | 204 | 179 | 198 | 163 | 191 | 159 | 240 | 369 | 370 |
| EPS in Rs | 2.25 | 3.35 | 2.16 | 5.73 | 5.12 | 5.59 | 4.64 | 5.43 | 4.41 | 6.53 | 10.06 | 10.09 |
| Dividend Payout % | 67% | 60% | 116% | 52% | 5% | 54% | 65% | 74% | 57% | 46% | 35% | 35% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 49.38% | -38.84% | 175.68% | -12.25% | 10.61% | -17.68% | 17.18% | -16.75% | 50.94% | 53.75% | 0.27% |
| Change in YoY Net Profit Growth (%) | 0.00% | -88.23% | 214.52% | -187.93% | 22.87% | -28.29% | 34.85% | -33.93% | 67.70% | 2.81% | -53.48% |
Jyothy Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 11% |
| 3 Years: | 9% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 16% |
| 3 Years: | 32% |
| TTM: | 3% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 19% |
| 3 Years: | 21% |
| 1 Year: | -39% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 17% |
| 3 Years: | 18% |
| Last Year: | 19% |
Last Updated: September 5, 2025, 8:35 am
Balance Sheet
Last Updated: November 9, 2025, 2:20 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 18 | 18 | 18 | 18 | 18 | 37 | 37 | 37 | 37 | 37 | 37 | 37 |
| Reserves | 716 | 762 | 883 | 1,071 | 1,126 | 1,290 | 1,192 | 1,392 | 1,407 | 1,512 | 1,772 | 2,013 |
| Borrowings | 534 | 569 | 451 | 498 | 544 | 281 | 285 | 117 | 171 | 47 | 51 | 61 |
| Other Liabilities | 386 | 468 | 417 | 266 | 291 | 335 | 323 | 410 | 408 | 466 | 542 | 580 |
| Total Liabilities | 1,654 | 1,817 | 1,770 | 1,853 | 1,979 | 1,942 | 1,836 | 1,956 | 2,023 | 2,062 | 2,401 | 2,691 |
| Fixed Assets | 1,094 | 1,074 | 1,068 | 1,097 | 1,091 | 1,101 | 1,149 | 1,147 | 1,122 | 1,116 | 1,125 | 1,141 |
| CWIP | 4 | 16 | 8 | 9 | 15 | 14 | 24 | 10 | 8 | 15 | 13 | 22 |
| Investments | 61 | 194 | 86 | 28 | 113 | 104 | 0 | 0 | 0 | 0 | 192 | 456 |
| Other Assets | 494 | 533 | 608 | 719 | 760 | 723 | 662 | 799 | 893 | 930 | 1,071 | 1,071 |
| Total Assets | 1,654 | 1,817 | 1,770 | 1,853 | 1,979 | 1,942 | 1,836 | 1,956 | 2,023 | 2,062 | 2,401 | 2,691 |
Below is a detailed analysis of the balance sheet data for Jyothy Labs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 37.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 37.00 Cr..
- For Reserves, as of Mar 2025, the value is 2,013.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,772.00 Cr. (Mar 2024) to 2,013.00 Cr., marking an increase of 241.00 Cr..
- For Borrowings, as of Mar 2025, the value is 61.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 51.00 Cr. (Mar 2024) to 61.00 Cr., marking an increase of 10.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 580.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 542.00 Cr. (Mar 2024) to 580.00 Cr., marking an increase of 38.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 2,691.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,401.00 Cr. (Mar 2024) to 2,691.00 Cr., marking an increase of 290.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 1,141.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,125.00 Cr. (Mar 2024) to 1,141.00 Cr., marking an increase of 16.00 Cr..
- For CWIP, as of Mar 2025, the value is 22.00 Cr.. The value appears strong and on an upward trend. It has increased from 13.00 Cr. (Mar 2024) to 22.00 Cr., marking an increase of 9.00 Cr..
- For Investments, as of Mar 2025, the value is 456.00 Cr.. The value appears strong and on an upward trend. It has increased from 192.00 Cr. (Mar 2024) to 456.00 Cr., marking an increase of 264.00 Cr..
- For Other Assets, as of Mar 2025, the value is 1,071.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 1,071.00 Cr..
- For Total Assets, as of Mar 2025, the value is 2,691.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,401.00 Cr. (Mar 2024) to 2,691.00 Cr., marking an increase of 290.00 Cr..
Notably, the Reserves (2,013.00 Cr.) exceed the Borrowings (61.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -380.00 | -405.00 | -228.00 | -243.00 | -287.00 | 1.00 | -34.00 | 198.00 | 77.00 | 269.00 | 429.00 | 439.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 18 | 14 | 22 | 25 | 35 | 31 | 26 | 18 | 24 | 20 | 27 | 35 |
| Inventory Days | 91 | 87 | 81 | 80 | 79 | 76 | 91 | 101 | 85 | 77 | 74 | 84 |
| Days Payable | 59 | 62 | 70 | 61 | 63 | 67 | 53 | 69 | 67 | 55 | 72 | 75 |
| Cash Conversion Cycle | 51 | 39 | 32 | 45 | 51 | 40 | 65 | 49 | 41 | 42 | 29 | 45 |
| Working Capital Days | 16 | -32 | -114 | -85 | -87 | -33 | -27 | -8 | -1 | 13 | 40 | 39 |
| ROCE % | 11% | 10% | 15% | 16% | 15% | 17% | 14% | 18% | 13% | 18% | 27% | 25% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 9,798,362 | 0.87 | 528.92 | 9,798,362 | 2025-04-22 17:25:29 | 0% |
| Franklin India Flexi Cap Fund | 4,112,112 | 1.24 | 221.97 | 4,112,112 | 2025-04-22 17:25:29 | 0% |
| Franklin India Smaller Companies Fund | 3,516,504 | 1.32 | 189.82 | 3,516,504 | 2025-04-22 02:06:43 | 0% |
| Axis Small Cap Fund | 2,803,873 | 0.64 | 151.35 | 2,803,873 | 2025-04-22 17:25:29 | 0% |
| Canara Robeco Small Cap Fund | 2,521,750 | 1.11 | 136.12 | 2,521,750 | 2025-04-22 17:25:29 | 0% |
| Canara Robeco Flexi Cap Fund | 2,211,183 | 0.88 | 119.36 | 2,211,183 | 2025-04-22 17:25:29 | 0% |
| HSBC Small Cap Fund - Regular Plan | 2,184,602 | 0.69 | 117.92 | 2,184,602 | 2025-04-22 17:25:29 | 0% |
| Mirae Asset Great Consumer Fund | 2,023,943 | 2.58 | 109.25 | 2,023,943 | 2025-04-22 17:25:29 | 0% |
| Canara Robeco Equity Hybrid Fund | 1,795,000 | 0.9 | 99.96 | 1,795,000 | 2025-04-22 17:25:29 | 0% |
| Canara Robeco ELSS Tax Saver Fund | 1,756,100 | 1.05 | 94.79 | 1,756,100 | 2025-04-22 17:25:29 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 10.09 | 10.06 | 6.53 | 4.41 | 5.43 |
| Diluted EPS (Rs.) | 10.09 | 10.06 | 6.53 | 4.41 | 5.43 |
| Cash EPS (Rs.) | 11.62 | 11.42 | 7.89 | 5.92 | 6.71 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 55.81 | 49.30 | 42.24 | 38.20 | 37.87 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 55.81 | 49.30 | 42.24 | 38.20 | 37.87 |
| Revenue From Operations / Share (Rs.) | 77.53 | 75.08 | 67.70 | 59.82 | 51.99 |
| PBDIT / Share (Rs.) | 15.12 | 14.53 | 9.68 | 7.27 | 9.07 |
| PBIT / Share (Rs.) | 13.59 | 13.17 | 8.31 | 5.68 | 7.55 |
| PBT / Share (Rs.) | 13.31 | 13.04 | 8.15 | 5.36 | 6.39 |
| Net Profit / Share (Rs.) | 10.09 | 10.06 | 6.53 | 4.33 | 5.19 |
| NP After MI And SOA / Share (Rs.) | 10.09 | 10.06 | 6.53 | 4.41 | 5.43 |
| PBDIT Margin (%) | 19.50 | 19.35 | 14.29 | 12.15 | 17.44 |
| PBIT Margin (%) | 17.52 | 17.54 | 12.27 | 9.50 | 14.52 |
| PBT Margin (%) | 17.16 | 17.36 | 12.03 | 8.96 | 12.29 |
| Net Profit Margin (%) | 13.00 | 13.39 | 9.64 | 7.24 | 9.98 |
| NP After MI And SOA Margin (%) | 13.01 | 13.40 | 9.64 | 7.37 | 10.44 |
| Return on Networth / Equity (%) | 18.07 | 20.43 | 15.47 | 11.22 | 13.96 |
| Return on Capital Employeed (%) | 22.89 | 25.18 | 18.44 | 13.89 | 18.69 |
| Return On Assets (%) | 13.76 | 15.38 | 11.62 | 8.00 | 10.19 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.08 | 0.08 |
| Asset Turnover Ratio (%) | 1.12 | 1.24 | 1.45 | 1.27 | 1.16 |
| Current Ratio (X) | 2.76 | 2.37 | 1.91 | 1.39 | 1.32 |
| Quick Ratio (X) | 2.12 | 1.78 | 1.16 | 0.81 | 0.73 |
| Inventory Turnover Ratio (X) | 9.31 | 4.25 | 4.32 | 3.81 | 3.18 |
| Dividend Payout Ratio (NP) (%) | 34.69 | 29.81 | 38.29 | 90.68 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 30.12 | 26.26 | 31.67 | 66.72 | 0.00 |
| Earning Retention Ratio (%) | 65.31 | 70.19 | 61.71 | 9.32 | 0.00 |
| Cash Earning Retention Ratio (%) | 69.88 | 73.74 | 68.33 | 33.28 | 0.00 |
| Interest Coverage Ratio (X) | 93.62 | 112.80 | 27.15 | 22.61 | 17.31 |
| Interest Coverage Ratio (Post Tax) (X) | 64.18 | 79.08 | 18.78 | 14.48 | 12.13 |
| Enterprise Value (Cr.) | 11925.68 | 15977.96 | 6732.28 | 5292.85 | 4910.52 |
| EV / Net Operating Revenue (X) | 4.19 | 5.80 | 2.71 | 2.41 | 2.57 |
| EV / EBITDA (X) | 21.48 | 29.95 | 18.94 | 19.83 | 14.75 |
| MarketCap / Net Operating Revenue (X) | 4.24 | 5.86 | 2.82 | 2.47 | 2.63 |
| Retention Ratios (%) | 65.30 | 70.18 | 61.70 | 9.31 | 0.00 |
| Price / BV (X) | 5.89 | 8.93 | 4.53 | 3.75 | 3.52 |
| Price / Net Operating Revenue (X) | 4.24 | 5.86 | 2.82 | 2.47 | 2.63 |
| EarningsYield | 0.03 | 0.02 | 0.03 | 0.02 | 0.03 |
After reviewing the key financial ratios for Jyothy Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 10.09. This value is within the healthy range. It has increased from 10.06 (Mar 24) to 10.09, marking an increase of 0.03.
- For Diluted EPS (Rs.), as of Mar 25, the value is 10.09. This value is within the healthy range. It has increased from 10.06 (Mar 24) to 10.09, marking an increase of 0.03.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.62. This value is within the healthy range. It has increased from 11.42 (Mar 24) to 11.62, marking an increase of 0.20.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 55.81. It has increased from 49.30 (Mar 24) to 55.81, marking an increase of 6.51.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 55.81. It has increased from 49.30 (Mar 24) to 55.81, marking an increase of 6.51.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 77.53. It has increased from 75.08 (Mar 24) to 77.53, marking an increase of 2.45.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 15.12. This value is within the healthy range. It has increased from 14.53 (Mar 24) to 15.12, marking an increase of 0.59.
- For PBIT / Share (Rs.), as of Mar 25, the value is 13.59. This value is within the healthy range. It has increased from 13.17 (Mar 24) to 13.59, marking an increase of 0.42.
- For PBT / Share (Rs.), as of Mar 25, the value is 13.31. This value is within the healthy range. It has increased from 13.04 (Mar 24) to 13.31, marking an increase of 0.27.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 10.09. This value is within the healthy range. It has increased from 10.06 (Mar 24) to 10.09, marking an increase of 0.03.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 10.09. This value is within the healthy range. It has increased from 10.06 (Mar 24) to 10.09, marking an increase of 0.03.
- For PBDIT Margin (%), as of Mar 25, the value is 19.50. This value is within the healthy range. It has increased from 19.35 (Mar 24) to 19.50, marking an increase of 0.15.
- For PBIT Margin (%), as of Mar 25, the value is 17.52. This value is within the healthy range. It has decreased from 17.54 (Mar 24) to 17.52, marking a decrease of 0.02.
- For PBT Margin (%), as of Mar 25, the value is 17.16. This value is within the healthy range. It has decreased from 17.36 (Mar 24) to 17.16, marking a decrease of 0.20.
- For Net Profit Margin (%), as of Mar 25, the value is 13.00. This value exceeds the healthy maximum of 10. It has decreased from 13.39 (Mar 24) to 13.00, marking a decrease of 0.39.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 13.01. This value is within the healthy range. It has decreased from 13.40 (Mar 24) to 13.01, marking a decrease of 0.39.
- For Return on Networth / Equity (%), as of Mar 25, the value is 18.07. This value is within the healthy range. It has decreased from 20.43 (Mar 24) to 18.07, marking a decrease of 2.36.
- For Return on Capital Employeed (%), as of Mar 25, the value is 22.89. This value is within the healthy range. It has decreased from 25.18 (Mar 24) to 22.89, marking a decrease of 2.29.
- For Return On Assets (%), as of Mar 25, the value is 13.76. This value is within the healthy range. It has decreased from 15.38 (Mar 24) to 13.76, marking a decrease of 1.62.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.12. It has decreased from 1.24 (Mar 24) to 1.12, marking a decrease of 0.12.
- For Current Ratio (X), as of Mar 25, the value is 2.76. This value is within the healthy range. It has increased from 2.37 (Mar 24) to 2.76, marking an increase of 0.39.
- For Quick Ratio (X), as of Mar 25, the value is 2.12. This value exceeds the healthy maximum of 2. It has increased from 1.78 (Mar 24) to 2.12, marking an increase of 0.34.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.31. This value exceeds the healthy maximum of 8. It has increased from 4.25 (Mar 24) to 9.31, marking an increase of 5.06.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 34.69. This value is within the healthy range. It has increased from 29.81 (Mar 24) to 34.69, marking an increase of 4.88.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 30.12. This value is within the healthy range. It has increased from 26.26 (Mar 24) to 30.12, marking an increase of 3.86.
- For Earning Retention Ratio (%), as of Mar 25, the value is 65.31. This value is within the healthy range. It has decreased from 70.19 (Mar 24) to 65.31, marking a decrease of 4.88.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 69.88. This value is within the healthy range. It has decreased from 73.74 (Mar 24) to 69.88, marking a decrease of 3.86.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 93.62. This value is within the healthy range. It has decreased from 112.80 (Mar 24) to 93.62, marking a decrease of 19.18.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 64.18. This value is within the healthy range. It has decreased from 79.08 (Mar 24) to 64.18, marking a decrease of 14.90.
- For Enterprise Value (Cr.), as of Mar 25, the value is 11,925.68. It has decreased from 15,977.96 (Mar 24) to 11,925.68, marking a decrease of 4,052.28.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.19. This value exceeds the healthy maximum of 3. It has decreased from 5.80 (Mar 24) to 4.19, marking a decrease of 1.61.
- For EV / EBITDA (X), as of Mar 25, the value is 21.48. This value exceeds the healthy maximum of 15. It has decreased from 29.95 (Mar 24) to 21.48, marking a decrease of 8.47.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.24. This value exceeds the healthy maximum of 3. It has decreased from 5.86 (Mar 24) to 4.24, marking a decrease of 1.62.
- For Retention Ratios (%), as of Mar 25, the value is 65.30. This value is within the healthy range. It has decreased from 70.18 (Mar 24) to 65.30, marking a decrease of 4.88.
- For Price / BV (X), as of Mar 25, the value is 5.89. This value exceeds the healthy maximum of 3. It has decreased from 8.93 (Mar 24) to 5.89, marking a decrease of 3.04.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.24. This value exceeds the healthy maximum of 3. It has decreased from 5.86 (Mar 24) to 4.24, marking a decrease of 1.62.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.03, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Jyothy Labs Ltd:
- Net Profit Margin: 13%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 22.89% (Industry Average ROCE: 29.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 18.07% (Industry Average ROE: 22.42%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 64.18
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.12
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 31.1 (Industry average Stock P/E: 46.51)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 13%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Personal Care | Ujala House, Ramkrishna Mandir Road, Mumbai Maharashtra 400059 | info@jyothy.com http://www.jyothylabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. M P Ramachandran | Chairman Emeritus |
| Ms. M R Jyothy | Chairperson & Managing Director |
| Mr. Ravi Razdan | Director |
| Mr. T Ananth Rao | Director - Commercial & Operations |
| Mr. Suresh Balakrishna | Independent Director |
| Ms. Bhumika Batra | Independent Director |
| Mr. Narayanan Subramaniam | Independent Director |
| Mr. Aditya Sapru | Independent Director |
FAQ
What is the intrinsic value of Jyothy Labs Ltd?
Jyothy Labs Ltd's intrinsic value (as of 21 November 2025) is 266.76 which is 13.95% lower the current market price of 310.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 11,389 Cr. market cap, FY2025-2026 high/low of 433/268, reserves of ₹2,013 Cr, and liabilities of 2,691 Cr.
What is the Market Cap of Jyothy Labs Ltd?
The Market Cap of Jyothy Labs Ltd is 11,389 Cr..
What is the current Stock Price of Jyothy Labs Ltd as on 21 November 2025?
The current stock price of Jyothy Labs Ltd as on 21 November 2025 is 310.
What is the High / Low of Jyothy Labs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Jyothy Labs Ltd stocks is 433/268.
What is the Stock P/E of Jyothy Labs Ltd?
The Stock P/E of Jyothy Labs Ltd is 31.1.
What is the Book Value of Jyothy Labs Ltd?
The Book Value of Jyothy Labs Ltd is 55.8.
What is the Dividend Yield of Jyothy Labs Ltd?
The Dividend Yield of Jyothy Labs Ltd is 1.13 %.
What is the ROCE of Jyothy Labs Ltd?
The ROCE of Jyothy Labs Ltd is 24.6 %.
What is the ROE of Jyothy Labs Ltd?
The ROE of Jyothy Labs Ltd is 19.0 %.
What is the Face Value of Jyothy Labs Ltd?
The Face Value of Jyothy Labs Ltd is 1.00.